This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Mar 1;28(7):e115-6; author reply e117-8.

doi: 10.1200/JCO.2009.26.7930. Epub 2010 Jan 25.

Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia

Kalman Filanovsky, Lev Shvidel, Mordechai Shtalrid

PMID: 20100951
DOI: 10.1200/JCO.2009.26.7930

Comment

Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia

Kalman Filanovsky et al. J Clin Oncol. 2010.

. 2010 Mar 1;28(7):e115-6; author reply e117-8.

doi: 10.1200/JCO.2009.26.7930. Epub 2010 Jan 25.

Authors

Kalman Filanovsky, Lev Shvidel, Mordechai Shtalrid

PMID: 20100951
DOI: 10.1200/JCO.2009.26.7930

No abstract available

PubMed Disclaimer

Comment on

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.

Similar articles

[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Hirayama Y, Terui T, Koike K, Neda H, Ishitani K, Kohda K, Kuroda H, Iyama S, Sato T, Kobune M, Takimoto R, Kato J. Hirayama Y, et al. Rinsho Ketsueki. 2009 Aug;50(8):663-5. Rinsho Ketsueki. 2009. PMID: 19915382 Japanese.
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R. Bahashwan S, et al. Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30370957 No abstract available.
Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.
Doyen J, Italiano A, Peyrade F, Bouyer C, Thyss A. Doyen J, et al. Br J Haematol. 2008 May;141(5):744-5. doi: 10.1111/j.1365-2141.2008.07096.x. Epub 2008 Mar 27. Br J Haematol. 2008. PMID: 18373704 Clinical Trial. No abstract available.
[Combination chemotherapy for acute myeloid leukemia].
Nagai T. Nagai T. Nihon Rinsho. 2009 Oct;67(10):1921-5. Nihon Rinsho. 2009. PMID: 19860191 Review. Japanese.
[Chemotherapy of relapsed AML and ALL].
Nishikawa K. Nishikawa K. Rinsho Ketsueki. 1996 Aug;37(8):647-50. Rinsho Ketsueki. 1996. PMID: 8827871 Review. Japanese. No abstract available.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information